Similar Search Results

Patents for Covid-19 vaccines are based on public research: a case study on the privatization of knowledge

Florio, Massimo - 2021 - This version October 11, 2021

Persistent link: https://www.econbiz.de/10012642904

The Dual Effects of Intellectual Property Regulations : Within- and Between- Patent Competition in the US Pharmaceuticals Industry

Lichtenberg, Frank R. - 2002

A patent only protects an innovator from others producing the same product, but it does not protect him from others … within-patent competition, which results from production of the same product, and betweenpatent competition, which results … effects of intellectual property regulations on within -patent competition by showing how protecting innovative returns from …

Persistent link: https://www.econbiz.de/10012469403

TRIPS flexibilities on patent enforcement : lessons from some developed countries relating to pharmaceutical patent protection

Sarnoff, Joshua D. - 2020

Persistent link: https://www.econbiz.de/10012433661

A Trojan horse inside the gates? : knowledge spillovers during patent litigation

Awate, Kiran Sharad; Makhija, Mona Verma - In: Academy of Management journal : AMJ 65 (2022) 5, pp. 1747-1769

Persistent link: https://www.econbiz.de/10013472203

Patent Laws in Light of New Realities in the US Pharmaceutical Industry

Shafee, Fariel - 2023

Patent laws protect innovations while offering incentive to discover new products. However, especially in the context … mechanism may not reflect the original concepts behind granting patents. Modification of patent laws as well as regulation of …

Persistent link: https://www.econbiz.de/10014255807

The Effect of Intellectual Property Rights on Domestic Innovation in the Pharmaceutical Sector

Gamba, Simona - 2016

. Domestic innovation is measured as citation-weighted domestic patents filed at the European Patent Office (EPO): to account for … to patent at the EPO. Results show that, in the short-run, IPR stimulate innovation. The effect for developing countries …

Persistent link: https://www.econbiz.de/10012984725

Is it Possible to Have Cheaper Drugs and Preserve the Incentive to Innovate? The Benefits of Privatizing the Drug Approval Process

Sauer, Corinne; Sauer, Robert M. - 2015

In this paper, we argue that lower prices for pharmaceuticals can be achieved by fostering a new type of competition in the pharmaceutical industry. Lower drug development costs, and hence prices, can be brought about by abolishing national drug administrations and replacing them with private...

Persistent link: https://www.econbiz.de/10014060120

Innovation Adoption by Committee : Evaluating Decision-Making in the FDA

Canen, Nathan J.; Iaryczower, Matiás - National Bureau of Economic Research - 2024

The FDA is responsible for the approval of new drugs, biological products and medical devices in the United States. As part of the approval process, the FDA relies on advisory committees, which provide independent advice from outside experts. We combine a structural approach with newly collected...

Persistent link: https://www.econbiz.de/10015056111

Agony in the Antipodes : The Generic Drug Provisions of the Australia-U.S. Free Trade Agreement

Outterson, Kevin - 2005

The Australia-U.S. Free Trade Agreement (AUSFTA), which entered into force on January 1, 2005, contains many remarkable provisions of interest to generic drug companies. The AUSFTA selectively exports U.S. generic drug laws of great import to generic drug manufacturers, and is uniquely intrusive...

Persistent link: https://www.econbiz.de/10014062769

The national regulation of pharmaceutical markets and the timing of new drug launches in Europe

Heuer, Alexander (contributor); Mejer, Malwina (contributor) - 2007

We analyze the impact of national pharmaceutical regulation on the launch delay of new chemical entities approved by the EMEA's centralized procedure. We find that direct price control regimes have a significantly negative impact on the launch timing. These results cannot be found when...

Persistent link: https://www.econbiz.de/10003471161